SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the public to finance its research of potential new treatments for both cancer and infectious disease.

In paperwork filed with securities regulators late last week, SQZ set a preliminary $75 million goal for its IPO. The Watertown, MA-based biotech has applied for a listing on the New York Stock Exchange under the stock symbol “SQZ.”

SQZ (pronounced “squeeze”) is developing technology intended to improve cell therapy. Current cell therapies get the therapeutic cargo into a cell via an... Read more »

Reprints | Share:   Retweet  Facebook  LinkedIn  Google Plus  E-mail